Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The common shares are priced at $0.795 each, with warrants priced at $0.005 each and an exercise price of $0.84 per share. The combined gross proceeds are expected to be approximately $2.9 million, with the transactions slated to close on or about Aug. 14, 2026, subject to customary closing conditions.
This financing is a strategic move for Dyadic, a global biotechnology company focused on developing and commercializing scalable, non-animal protein production platforms. The net proceeds, along with existing cash and cash equivalents, will be allocated for working capital and general corporate purposes, providing the company with additional runway to advance its proprietary Dapibus™ and C1 expression systems. These systems are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins, catering to the life sciences, food and nutrition, and bio-industrial markets.
The announcement comes at a time when the demand for sustainable and efficient protein production is rising. Dyadic's platforms aim to meet this demand by offering alternatives to animal-based proteins, which are often less scalable and more resource-intensive. By securing this capital, Dyadic is positioning itself to capitalize on the growing global need for sustainable biotech solutions, potentially transforming how proteins are produced across multiple industries.
For investors, this offering represents a vote of confidence from an institutional investor, indicating belief in Dyadic's technology and market potential. The exercise price of the warrants, set at $0.84 per share, suggests a positive outlook for the company's stock price over the long term. The involvement of Aegis Capital Corp. as exclusive placement agent further validates the offering's structure and potential success.
Dyadic's focus on non-animal protein platforms is particularly relevant as industries face increasing pressure to reduce environmental footprints and improve supply chain resilience. The company's C1 expression system, in particular, is noted for its ability to produce proteins efficiently, which could lead to lower costs and higher scalability compared to traditional methods.
The successful completion of this offering will not only provide immediate working capital but also enhance Dyadic's financial flexibility to pursue strategic partnerships and product development initiatives. As the company continues to innovate in the biotech space, this capital infusion is a critical step toward achieving its long-term goals.
For more information on the offering, visit https://ibn.fm/od7FJ. To learn more about Dyadic International, visit https://dyadic.com/.
